Definitive pelvic radiotherapy was associated with longer survival in stage IVB cervical cancer
Median survival was 25 versus 18 months with chemotherapy plus definitive pelvic radiotherapy after propensity matching in stage IVB cervical cancer.
Tag
High relevance
Hypofractionated salvage radiotherapy did not improve biochemical control after prostatectomy
Four-year biochemical control was similar with 65 Gy in 26 fractions and 66 Gy in 33 fractions, while gastrointestinal toxicity was higher.
Long-course chemoradiotherapy improved early organ preservation in STAR-TREC
Twelve-month TME-free survival was 78.5% with long-course chemoradiotherapy versus 60.6% with short-course radiotherapy in early rectal cancer.
Whole-pelvic radiotherapy did not improve survival in high-risk node-negative prostate cancer
Across five phase III trials, whole-pelvic radiotherapy did not improve overall survival, and progression benefits disappeared when POP-RT was excluded.
Overlap-adapted dose reduction lowered temporal lobe injury in T4 nasopharyngeal cancer
Reducing the PTV–temporal lobe overlap dose to 66 Gy lowered five-year radiographic temporal lobe injury from 36.2% to 23.2%.
Lithium mouthwash reduced severe oral mucositis during head and neck radiotherapy
Lithium mouthwash reduced severe oral mucositis from 52.1% to 34.2% in a randomized phase II head and neck radiotherapy trial.
Induction TPF did not improve three-year PFS over adjuvant PF in locally advanced NPC
Three-year PFS was 79.0% with induction TPF versus 74.5% with adjuvant PF, with substantially different toxicity profiles.
Proton breast radiotherapy caused more acute dermatitis than photons in randomized DBCG substudy
Grade 2–3 dermatitis reached 71% with protons versus 20% with photons, but resolved within weeks and other acute toxicity was similar.
Cervical cancer advanced by one stage approximately every 8.6 weeks before radiotherapy
Cervical cancer stage progression was estimated every 8.6 weeks of treatment delay and was faster among women living with HIV.
Five-fraction prostate and pelvic SABR showed durable control with low late toxicity
Five weekly SABR fractions to prostate and pelvic nodes produced 10.5% five-year biochemical failure with low persistent gastrointestinal and urinary toxicity.
Updated ASTRO guideline expands radiation therapy across pancreatic cancer settings
ASTRO expands radiation therapy recommendations across locally advanced, recurrent and oligometastatic pancreatic cancer, with new guidance on dose escalation and adaptation.
AI biomarker substantially reduced planned ADT use in intermediate-risk prostate cancer
ASTuTE biomarker testing changed 27.5% of shared decisions and reduced planned short-term ADT use from 37% to 12.5%.
Six-fraction chemoradiation worsened survival in newly diagnosed glioblastoma
Six-fraction chemoradiation shortened median survival from 21 to 13 months and substantially increased radiation necrosis compared with standard treatment.
SUPREMO radiotherapy modestly worsened chest wall symptoms without broader quality-of-life loss
EXCERPT At five years, chest wall radiotherapy modestly worsened local symptoms but did not significantly affect overall quality of life or major functional domains.
Most European proton candidates still face critical access shortages
More than 56,000 theoretically eligible European patients lived in areas with no proton access or critical capacity shortages in 2025.